alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid has been researched along with Depression in 11 studies
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid: An IBOTENIC ACID homolog and glutamate agonist. The compound is the defining agonist for the AMPA subtype of glutamate receptors (RECEPTORS, AMPA). It has been used as a radionuclide imaging agent but is more commonly used as an experimental tool in cell biological studies.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "D-serine has attracted increasing attention for its possible role in depression." | 4.12 | L-4-Fluorophenylglycine produces antidepressant-like effects and enhances resilience to stress in mice. ( Chan, MH; Chang, WT; Chen, HH; Kuo, TH; Sung, CW, 2022) |
| "In this study, we tested whether AMPA alone has an antidepressant effect and if the combination of AMPA and ketamine provides added benefit in Wistar-Kyoto rats, a putative animal model of depression." | 3.79 | Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. ( Akinfiresoye, L; Tizabi, Y, 2013) |
| "Org 26576 is an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor positive allosteric modulator that acts by modulating ionotropic AMPA-type glutamate receptors to enhance glutamatergic neurotransmission." | 2.77 | Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection. ( Bursi, R; Dogterom, P; Ereshefsky, L; Gertsik, L; Mant, T; Nations, KR; Schipper, J, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, W | 1 |
| Yang, Y | 1 |
| Chen, X | 2 |
| Mei, Y | 1 |
| Li, X | 1 |
| An, L | 1 |
| Sung, CW | 1 |
| Chang, WT | 1 |
| Chan, MH | 1 |
| Kuo, TH | 1 |
| Chen, HH | 1 |
| Huang, S | 1 |
| Zheng, C | 1 |
| Xie, G | 1 |
| Song, Z | 1 |
| Wang, P | 1 |
| Bai, Y | 1 |
| Chen, D | 1 |
| Zhang, Y | 1 |
| Lv, P | 1 |
| Liang, W | 1 |
| She, S | 1 |
| Li, Q | 1 |
| Liu, Z | 1 |
| Wang, Y | 3 |
| Xing, GG | 1 |
| Li, MX | 1 |
| Zheng, HL | 1 |
| Luo, Y | 1 |
| He, JG | 1 |
| Wang, W | 1 |
| Han, J | 1 |
| Zhang, L | 1 |
| Wang, X | 1 |
| Ni, L | 1 |
| Zhou, HY | 1 |
| Hu, ZL | 1 |
| Wu, PF | 1 |
| Jin, Y | 1 |
| Long, LH | 1 |
| Zhang, H | 1 |
| Hu, G | 1 |
| Chen, JG | 1 |
| Wang, F | 1 |
| Akinfiresoye, L | 1 |
| Tizabi, Y | 1 |
| Pochwat, B | 1 |
| Sowa-Kucma, M | 1 |
| Kotarska, K | 1 |
| Misztak, P | 1 |
| Nowak, G | 1 |
| Szewczyk, B | 1 |
| Korpi, ER | 1 |
| den Hollander, B | 1 |
| Farooq, U | 1 |
| Vashchinkina, E | 1 |
| Rajkumar, R | 1 |
| Nutt, DJ | 1 |
| Hyytiä, P | 1 |
| Dawe, GS | 1 |
| Shimizu, K | 1 |
| Kurosawa, N | 1 |
| Seki, K | 1 |
| Xie, Y | 1 |
| Huang, X | 1 |
| Hu, SY | 1 |
| Zhang, YJ | 1 |
| Qiu, XJ | 1 |
| Ren, P | 1 |
| Fan, R | 1 |
| Zhang, CH | 1 |
| Xie, WB | 1 |
| Ji, H | 1 |
| He, J | 1 |
| Xie, L | 1 |
| Liu, ZQ | 1 |
| Zhou, HH | 1 |
| Nations, KR | 1 |
| Bursi, R | 1 |
| Dogterom, P | 1 |
| Ereshefsky, L | 1 |
| Gertsik, L | 1 |
| Mant, T | 1 |
| Schipper, J | 1 |
| Hu, Y | 1 |
| Liu, X | 1 |
| Shen, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression[NCT04234776] | Phase 4 | 88 participants (Anticipated) | Interventional | 2018-04-03 | Enrolling by invitation | ||
| Evaluation of the Initial Prescription of Ketamine and Milnacipran Forin Depression in Patients With a Progressive Disease[NCT02783430] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2016-09-08 | Recruiting | ||
| A Safe Ketamine-Based Therapy for Treatment Resistant Depression[NCT01179009] | 20 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item scale that measures the severity of depression, with a higher score indicating a higher level of depression. The range of scores is 0 to 60. (NCT01179009)
Timeframe: 8 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Ketamine 100-hour Infusion | -9.0 |
| Ketamine 40-minute Infusion | -6.4 |
1 review available for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and Depression
| Article | Year |
|---|---|
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse.
Topics: Alcoholism; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amphetamines; Animals; Behavio | 2015 |
1 trial available for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and Depression
| Article | Year |
|---|---|
Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection.
Topics: Adolescent; Adult; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Depression; Depressive | 2012 |
9 other studies available for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and Depression
| Article | Year |
|---|---|
Prenatal cyanuric acid exposure disrupts cognitive flexibility and mGluR1-mediated hippocampal long-term depression in male rats.
Topics: Alkaline Phosphatase; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Cognition; | 2022 |
L-4-Fluorophenylglycine produces antidepressant-like effects and enhances resilience to stress in mice.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amin | 2022 |
FAM19A5/TAFA5, a novel neurokine, plays a crucial role in depressive-like and spatial memory-related behaviors in mice.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Biomarkers; Depression; Hippocamp | 2021 |
Gene deficiency and pharmacological inhibition of caspase-1 confers resilience to chronic social defeat stress via regulating the stability of surface AMPARs.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anxiety; Behavior, Animal; Caspas | 2018 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Antidepressant-like activity of magnesium in the olfactory bulbectomy model is associated with the AMPA/BDNF pathway.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amitriptyline; Animals; Antidepressive Age | 2015 |
The role of the AMPA receptor and 5-HT(3) receptor on aggressive behavior and depressive-like symptoms in chronic social isolation-reared mice.
Topics: Aggression; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amygdala; Animals; Depression; | 2016 |
The involvement of AMPA-ERK1/2-BDNF pathway in the mechanism of new antidepressant action of prokinetic meranzin hydrate.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |
Is mTOR involved in the mechanisms of the fast-acting antidepressant effects of AMPA receptor agonists?
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antidepressive Agents; Brain-Deri | 2013 |